Cicone, Francesco https://orcid.org/0000-0003-4664-1965
Denoƫl, Thibaut
Gnesin, Silvano
Riggi, Nicolo
Irving, Melita
Jakka, Gopinadh
Schaefer, Niklaus
Viertl, David
Coukos, George
Prior, John O.
Article History
First Online: 28 January 2020
Change Date: 20 March 2020
Change Type: Correction
Change Details: In the original article, some numerical values in the following paragraph were reported incorrectly.
Compliance with Ethical Standards
:
: George Coukos has received grants, research support or is coinvestigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance and Kite. Prof. Coukos has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx. Prof. Coukos has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. George Coukos holds patents around TEM1 antibodies and receives royalties from the University of Pennsylvania regarding technology licensed to Novartis. All other authors declare that they have no potential conflict of interest to disclose.
: All applicable institutional and/or national guidelines for the care and use of animals were followed. In particular, all animal experiments in the present study were conducted according to the Swiss federal law on animal experimentation under the authorization number VD-2993.
: This article does not contain any studies with human participants performed by any of the authors.